Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma

Christian Buske • 14 Jun 2017
ICML 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma Rituximab

Christian Buske, MD from the University Hospital Ulm, Ulm, Germany discusses the Phase III trial comparing the efficacy and safety of the biosimilar CT-P10 to rituximab in combination with CVP in advanced follicular lymphoma (NCT02162771). The rationale of the study was to establish if the biosimilar is indeed similar to the originator. Prof. Buske further discusses the potential of using the biosimilar in diffuse large B-cell lymphoma (DLBCL) based on extrapolation.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Christian Buske

Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
Christian Buske • 14 Jun 2017
2:48
BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
Christian Buske • 14 Jun 2017
2:41
ICML 2017 session on the biosimilar rituximab: challenges and data
Christian Buske • 14 Jun 2017

Related Videos

2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
1:30
Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II study
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals